Radius Health Inc (RDUS) : Rock Springs Capital Management Lp scooped up 24,500 additional shares in Radius Health Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 892,000 shares of Radius Health Inc which is valued at $48,408,840.Radius Health Inc makes up approximately 3.06% of Rock Springs Capital Management Lp’s portfolio.
Other Hedge Funds, Including , Balyasny Asset Management sold out all of its stake in RDUS during the most recent quarter. The investment firm sold 79,345 shares of RDUS which is valued $4,306,053. Sg Americas Securities added RDUS to its portfolio by purchasing 9,015 company shares during the most recent quarter which is valued at $378,630.Neuberger Berman Group reduced its stake in RDUS by selling 6,500 shares or 52.0% in the most recent quarter. The Hedge Fund company now holds 6,000 shares of RDUS which is valued at $237,360. Strs Ohio added RDUS to its portfolio by purchasing 200 company shares during the most recent quarter which is valued at $8,618.
Radius Health Inc closed down -0.42 points or -0.79% at $52.77 with 4,31,231 shares getting traded on Monday. Post opening the session at $53.58, the shares hit an intraday low of $52.19 and an intraday high of $54.44 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Radius Health Inc reported $-1.07 EPS for the quarter, based on the information available during the earnings call on Nov 3, 2016. Analyst had a consensus estimate of $-1.07.During the same quarter in the previous year, the company posted $-0.68 EPS.
Many Wall Street Analysts have commented on Radius Health Inc. Company shares were Reiterated by H.C. Wainwright on Sep 21, 2016 to “Buy”, Firm has raised the Price Target to $ 71 from a previous price target of $55 .
Radius Health Inc. is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company’s lead product candidate is abaloparatide (BA058) a bone anabolic for use in the reduction of fractures in postmenopausal osteoporosis delivered through subcutaneous injection which it refers to as abaloparatide-SC and is in Phase III development. The Company is leveraging its investment in Abaloparatide-SC to develop a line extension that is designed to improve patient convenience by enabling administration of abaloparatide through an investigational short-wear-time patch which the Company refers to as abaloparatide-TD. The Company’s clinical product portfolio also includes the investigational drug RAD1901 a selective estrogen receptor down regulator/degrader (SERD) and RAD140 a nonsteroidal selective androgen receptor modulator (SARM) for the treatment of breast cancer.